Inhibition of pentagastrin-stimulated and nocturnal gastric secretion by ranitidine. A new H2-receptor antagonist.
Ranitidine hydrochloride (an H2-receptor-blocking drug which does not contain the imidazole nucleus of histamine) powerfully inhibited nocturnal and pentagastrin-stimulated gastric secretion in fifteen patients with duodenal ulceration. The drug is satisfactorily absorbed and therefore warrants clinical trial.
D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D004341:Drug Evaluation; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005663:Furans / Q000494:pharmacology*; D005745:Gastric Acidity Determination; D005750:Gastric Juice / Q000187:drug effects / Q000378:metabolism*; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D010418:Pentagastrin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D013268:Stimulation, Chemical
D005663:Furans; D006635:Histamine H2 Antagonists; D010418:Pentagastrin